全文获取类型
收费全文 | 473篇 |
免费 | 78篇 |
国内免费 | 4篇 |
专业分类
综合类 | 8篇 |
化学工业 | 33篇 |
金属工艺 | 4篇 |
机械仪表 | 1篇 |
轻工业 | 498篇 |
无线电 | 3篇 |
一般工业技术 | 8篇 |
出版年
2024年 | 10篇 |
2023年 | 42篇 |
2022年 | 33篇 |
2021年 | 63篇 |
2020年 | 45篇 |
2019年 | 35篇 |
2018年 | 37篇 |
2017年 | 27篇 |
2016年 | 12篇 |
2015年 | 14篇 |
2014年 | 28篇 |
2013年 | 21篇 |
2012年 | 26篇 |
2011年 | 23篇 |
2010年 | 20篇 |
2009年 | 12篇 |
2008年 | 14篇 |
2007年 | 25篇 |
2006年 | 22篇 |
2005年 | 12篇 |
2004年 | 8篇 |
2003年 | 13篇 |
2002年 | 6篇 |
2001年 | 1篇 |
2000年 | 3篇 |
1999年 | 1篇 |
1998年 | 1篇 |
1980年 | 1篇 |
排序方式: 共有555条查询结果,搜索用时 31 毫秒
1.
Karina Polak Beata Bergler-Czop Micha Szczepanek Kamila Wojciechowska Aleksandra Frtczak Norbert Kiss 《International journal of molecular sciences》2021,22(9)
Psoriasis is a chronic, immune-mediated inflammatory disease that affects around 125 million people worldwide. Several studies concerning the gut microbiota composition and its role in disease pathogenesis recently demonstrated significant alterations among psoriatic patients. Certain parameters such as Firmicutes/Bacteroidetes ratio or Psoriasis Microbiome Index were developed in order to distinguish between psoriatic and healthy individuals. The “leaky gut syndrome” and bacterial translocation is considered by some authors as a triggering factor for the onset of the disease, as it promotes chronic systemic inflammation. The alterations were also found to resemble those in inflammatory bowel diseases, obesity and certain cardiovascular diseases. Microbiota dysbiosis, depletion in SCFAs production, increased amount of produced TMAO, dysregulation of the pathways affecting the balance between lymphocytes populations seem to be the most significant findings concerning gut physiology in psoriatic patients. The gut microbiota may serve as a potential response-to-treatment biomarker in certain cases of biological treatment. Oral probiotics administration as well as fecal microbial transplantation were most reported in bringing health benefits to psoriatic patients. However, the issue of psoriatic bacterial gut composition, its role and healing potential needs further investigation. Here we reviewed the literature on the current state of the relationship between psoriasis and gut microbiome. 相似文献
2.
Tolulope Joshua Ashaolu 《International Journal of Food Science & Technology》2021,56(8):3719-3725
Fervid interests on nanoparticles are increasing within the scientific and non-scientific communities, as they are utilised in food and non-food applications. The versatility of emerging applications of nanoparticles makes them potentially harmful to the food, healthcare and environment sectors, and thus necessitates the development of nanonutraceuticals from nutritional substances such as antioxidants, vitamins, fatty acids, fibres, probiotics and prebiotics. This review excavated state of the art on nanotechnology applications such as gold and selenium particles, nanolayers, nanobeads, nanoemulsions and nanofibers to probiotics and prebiotics for the synthesis of anticancer, antimicrobial, antioxidant and photo-reactive products among others, and finally delved into other noteworthy considerations like safety. It is concluded that available literature on the current status of nanoprobiotics and prebiotics are exhaustive, despite their huge potentials and applications. 相似文献
3.
长双歧杆菌(Bifidobacterium longum CCFM760)是一株从江苏省无锡市滨湖区两岁健康幼女粪便分离筛选得到的具有良好缓解便秘功效的益生菌。作者对其生长产酸能力、人工模拟肠胃液耐受性、抑菌能力、低聚糖利用能力、抗生素耐受能力和总超氧化物歧化酶(SOD)活性进行了检测。该菌具有良好的生长产酸能力和人工模拟肠胃液耐受性,对大肠杆菌和金黄色葡萄球菌有明显的抑制作用,能显著利用7种低聚糖,对14种抗生素敏感,培养液中总SOD活性达到(99.14±9.91)U/mL。此外,对该菌进行基因组草图测序,并从基因组角度解析了其低聚糖代谢能力、抗生素敏感性以及抗氧化能力。以上结果表明,B.longum CCFM760是一株安全的、具有实际应用潜力的益生菌。 相似文献
4.
以实验室77株益生菌为研究对象,从其菌体细胞代谢物(cell-free excretory supernatants,CFS)和细胞内容物(cell-free extracts,CFE)两方面分析菌株对α-葡萄糖苷酶的抑制活性;同时还从耐酸性、细胞黏附性等方面对具有α-葡萄糖苷酶抑制活性的菌株进行了益生特性评价;最后利用主成分分析进行综合性评价,以期筛选出具有α-葡萄糖苷酶抑制作用的益生菌。结果表明,77株益生菌的CFE对α-葡萄糖苷酶没有抑制作用;而CFS对α-葡萄糖苷酶具有一定的抑制作用,抑制率为2.53%~15.76%。选取抑制率明显高于其他益生菌(编号为ST-2、1.1881、GS-3和BLP12)菌株进行益生特性的研究。其中ST-2表现出很高的耐酸性和细胞黏附性;GS-3在模拟消化液中有很强的耐受性等,各菌株特性不一。主成分分析表明菌株BLP12的综合性能最好:其对α-葡萄糖苷酶的抑制率可达15.10%;于pH 2.0孵育3 h后,存活率能达到71.04%;于2.0%的胆盐条件下孵育24 h,存活率为0.70%;依次经模拟唾液、胃液、肠液消化后,存活率仍能达到88.27%,但对HT-29细胞的黏附率较低,仅为1.93%,总体上菌株BLP12对体外模拟胃肠环境的适应性很强。该菌株经过16S基因序列鉴定为植物乳杆菌,可作为降糖益生菌株应用于降糖食品的开发。 相似文献
5.
6.
选取6种商业益生菌分别对红枣汁进行发酵,研究其对红枣汁的抗氧化活性、理化指标及香气的影响。结果表明,益生菌发酵可显著提高红枣汁的抗氧化能力,果321复合菌发酵枣汁的DPPH自由基清除能力最强,为573.83 mg/L,而植物乳杆菌(Lactobacillus plantarum)发酵枣汁的ABTS自由基清除能力最强,为1 034.00 mg/L,瑞士乳杆菌(Lactobacillus helveticus)发酵枣汁的铁离子还原力(FRAP)值最高,为1 366.34 mg/L。瑞士乳杆菌的产酸性能较好,发酵后产乳酸量约0.45 mg/L,总多酚和总黄酮含量分别较红枣汁提高了2.94%和2.85%。电子鼻分析结果表明,益生菌发酵可显著改变红枣汁的香气成分,且线性判别分析(LDA)对红枣汁香气物质的区分和识别效果优于主成分分析(PCA),发酵红枣汁的特征风味主要来源于硫化物、萜烯类、广谱甲基类、氮氧化物、乙醇和芳香型化合物。 相似文献
7.
本研究以胡萝卜、牛蒡、山药等为原料,添加复合益生菌制备益生菌复合酸奶并对其发酵条件进行了优化。实验结果表明,胡萝卜、牛蒡、山药的添加质量分数分别为20%、15%和10%时,发酵温度在40℃时,时间在7 h条件下,发酵的复合益生菌酸奶品质最好。乳酸菌接种量为5%~6%时,复合益生菌酸奶的酸性约为80%,持水性约为70%;通过发酵温度和发酵时间的对比,证明复合益生菌酸奶最佳发酵条件为:接种量为5%,发酵时间为7 h,发酵温度为40℃。实验结果表明:所提发酵条件能够更好实现复合益生菌酸奶的发酵优化,且得到的酸奶发酵后质量最佳。 相似文献
8.
The impact of total solid (TS) content in combination with the feed rate and air inlet temperature on the survival of Lactobacillus paracasei ssp. paracasei F19 after spray drying in a skim milk matrix has been investigated and correlated with the capsule size. Depending on the experimental conditions, the survival rates ranged from 64 to 0.2%. The higher the air inlet temperature, the lower was the survival rate and an inversely correlation between the TS content and particle size has been determined. These results clearly indicate that process stress analyses and product-related characteristics must not be regarded separately. 相似文献
9.
Breast cancer is the most frequently diagnosed cancer in women worldwide. The disease and its treatments exert profound effects on an individual’s physical and mental health. There are many factors that impact an individual’s risk of developing breast cancer, their response to treatments, and their risk of recurrence. The community of microorganisms inhabiting the gastrointestinal tract, the gut microbiota, affects human health through metabolic, neural, and endocrine signaling, and immune activity. It is through these mechanisms that the gut microbiota appears to influence breast cancer risk, response to treatment, and recurrence. A disrupted gut microbiota or state of ‘dysbiosis’ can contribute to a biological environment associated with higher risk for cancer development as well as contribute to negative treatment side-effects. Many cancer treatments have been shown to shift the gut microbiota toward dysbiosis; however, the microbiota can also be positively manipulated through diet, prebiotic and probiotic supplementation, and exercise. The objective of this review is to provide an overview of the current understanding of the relationship between the gut microbiota and breast cancer and to highlight potential strategies for modulation of the gut microbiota that could lead to improved clinical outcomes and overall health in this population. 相似文献
10.
Atherosclerosis, the underlying cause of cardiovascular diseases such as myocardial infarction, cerebrovascular accident, and peripheral vascular disease, is the leading cause of global mortality. Current therapies against atherosclerosis, which mostly target the dyslipidemia associated with the disease, have considerable residual risk for cardiovascular disease together with various side effects. In addition, the outcomes from clinical trials on many promising pharmaceutical agents against atherosclerosis (e.g., low‐dose methotrexate, inhibitors against cholesteryl ester transfer protein) have been disappointing. Nutraceuticals such as probiotic bacteria have, therefore, generated substantial recent interest for the prevention of atherosclerosis and potentially as add‐ons with current pharmaceutical drugs. This review will discuss the current understanding of the anti‐atherogenic actions of probiotics from preclinical and clinical studies together with their potential underlying mechanisms of action. 相似文献